Clinical Trials Browser

Interventional × Recurrence × visilizumab × Clear all

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML

Phase 3 Unknown

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute